Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Published online 20 February 2008
Haematologica, Vol 93, Issue 3, 459-462 doi:10.3324/haematol.11687
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Google Scholar
Right arrow Articles by Bochtler, T.
Right arrow Articles by Schonland, S. O.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bochtler, T.
Right arrow Articles by Schonland, S. O.

Amyloidosis

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis

Tilmann Bochtler1, Ute Hegenbart1, Christiane Heiss2,4, Axel Benner2, Friedrich Cremer1, Martin Volkmann3, Jochen Ludwig3, Jolanta B. Perz1, Anthony D. Ho1, Hartmut Goldschmidt1, Stefan O. Schonland1,

1 Department of Internal Medicine Division of Hematology/Oncology, Amyloidosis Clinic, University of Heidelberg
2 Division of Biostatistics (C060), German Cancer Research Center, Heidelberg
3 Department of Internal Medicine I and Clinical Chemistry, University of Heidelberg
4 Department of Internal Medicine Division of Hematology/Oncology, University of Heidelberg, Germany

Correspondence: Stefan Schönland MD, Medizinische Klinik V, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. E-mail: stefan.schoenland{at}med.uni-heidelberg.de

We evaluated the Serum Free Light Chain (FLC) test in a series of 133 untreated patients with systemic AL amyloidosis. The FLC test detected the monoclonal gammopathy in 87% compared with 92% for immunofixation of serum and urine in combination. However, both tests proved complementary. The FLC test was also a valuable tool in patients with advanced renal failure in spite of uninvolved light chain retention. Higher FLC levels were associated with higher bone marrow plasmocytosis, poorer Karnofsky index and heart involvement, and therefore reflected disease severity.

Key words: serum-free light chain test, AL amyloidosis, Karnofsky index, bone marrow plasmocytosis, heart disease.




This article has been cited by other articles:


Home page
 BloodHome page
T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al.
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
Blood, May 1, 2008; 111(9): 4700 - 4705.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2008 by the Ferrata Storti Foundation.